136 related articles for article (PubMed ID: 2205353)
21. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis.
Morrison VA; Picozzi V; Scott S; Pohlman B; Dickman E; Lee M; Lawless G; Kerr R; Caggiano V; Delgado D; Fridman M; Ford J; Carter WB;
Clin Lymphoma; 2001 Jun; 2(1):47-56. PubMed ID: 11707870
[TBL] [Abstract][Full Text] [Related]
22. International prognostic index-based outcomes for diffuse large B-cell lymphomas.
Wilder RB; Rodriguez MA; Medeiros LJ; Tucker SL; Ha CS; Romaguera JE; Pro B; Hess MA; Cabanillas F; Cox JD
Cancer; 2002 Jun; 94(12):3083-8. PubMed ID: 12115338
[TBL] [Abstract][Full Text] [Related]
23. Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy.
Touroutoglou N; Dimopoulos MA; Younes A; Hess M; Pugh W; Cox J; Cabanillas F; Sarris AH
J Clin Oncol; 1995 Jun; 13(6):1361-7. PubMed ID: 7751880
[TBL] [Abstract][Full Text] [Related]
24. Deliverability and efficacy of R-CHOP chemotherapy in very elderly patients with diffuse large B-cell lymphoma: an Australian retrospective analysis.
Millar A; Ellis M; Mollee P; Cochrane T; Fletcher J; Caudron A; Webster B; Trotman J
Intern Med J; 2015 Nov; 45(11):1147-53. PubMed ID: 26337606
[TBL] [Abstract][Full Text] [Related]
25. Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas.
Schlembach PJ; Wilder RB; Tucker SL; Ha CS; Rodriguez MA; Hess MA; Cabanillas FF; Cox JD
Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1107-10. PubMed ID: 11072169
[TBL] [Abstract][Full Text] [Related]
26. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study.
Shipp MA; Neuberg D; Janicek M; Canellos GP; Shulman LN
J Clin Oncol; 1995 Dec; 13(12):2916-23. PubMed ID: 8523055
[TBL] [Abstract][Full Text] [Related]
27. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349
[TBL] [Abstract][Full Text] [Related]
28. Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
Mörth C; Valachis A; Sabaa AA; Molin D; Flogegård M; Enblad G
Ann Hematol; 2018 Nov; 97(11):2129-2135. PubMed ID: 30091025
[TBL] [Abstract][Full Text] [Related]
29. Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging.
Dorth JA; Prosnitz LR; Broadwater G; Diehl LF; Beaven AW; Coleman RE; Kelsey CR
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):762-7. PubMed ID: 22420972
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
31. Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas.
Schneider AM; Straus DJ; Schluger AE; Lowenthal DA; Koziner B; Lee BJ; Wong G; Clarkson BD
J Clin Oncol; 1990 Jan; 8(1):94-102. PubMed ID: 1688617
[TBL] [Abstract][Full Text] [Related]
32. Disseminated nonlymphoblastic lymphoma of childhood: a Childrens Cancer Group study, CCG-552.
Finlay JL; Anderson JR; Cecalupo AJ; Hutchinson RJ; Kadin ME; Kjeldsberg CR; Provisor AJ; Woods WG; Meadows AT
Med Pediatr Oncol; 1994; 23(6):453-63. PubMed ID: 7935170
[TBL] [Abstract][Full Text] [Related]
33. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease.
O'Reilly SE; Hoskins P; Klimo P; Connors JM
Ann Oncol; 1991 Jan; 2 Suppl 1():17-23. PubMed ID: 1710485
[TBL] [Abstract][Full Text] [Related]
34. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF
Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251
[TBL] [Abstract][Full Text] [Related]
35. Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone.
Chae YS; Shin H; Sohn SK; Lee SJ; Moon JH; Kang BW; Kim JG; Yang DH; Lee JJ; Park TI
Leuk Lymphoma; 2012 Sep; 53(9):1757-63. PubMed ID: 22372848
[TBL] [Abstract][Full Text] [Related]
36. [Treatment outcome in primary testicular non-Hodgkin lymphoma].
Iványi JL; Marton E; Plander M; Engert ZV; Tóth C
Orv Hetil; 2013 Oct; 154(42):1666-73. PubMed ID: 24121219
[TBL] [Abstract][Full Text] [Related]
37. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
[TBL] [Abstract][Full Text] [Related]
38. Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study.
Laver JH; Mahmoud H; Pick TE; Hutchison RE; Weinstein HJ; Schwenn M; Weitzman S; Murphy SB; Ochoa S; Shuster JJ
Leuk Lymphoma; 2002 Jan; 43(1):105-9. PubMed ID: 11908712
[TBL] [Abstract][Full Text] [Related]
39. Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-Hodgkin's lymphoma.
McMaster ML; Greer JP; Wolff SN; Johnson DH; Greco FA; Stein RS; Cousar JB; Flexner JM; Hainsworth JD
Cancer; 1991 Jul; 68(2):233-41. PubMed ID: 1712662
[TBL] [Abstract][Full Text] [Related]
40. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
